Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M83.4Revenue (TTM) $M15.9Net Margin (%)-151.0Altman Z-Score-53.2
Enterprise Value $M140EPS (TTM) $-0.1Operating Margin %-83.9Piotroski F-Score4
P/E(ttm)--Beneish M-Score-3.0Pre-tax Margin (%)-158.6Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio0.2Cash flow > EarningsY
Price/Sales5.35-y EBITDA Growth Rate %58.9Current Ratio0.2Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-153.9Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M156ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with NAVB

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NAVBJohn Keeley 2015-12-31 Sold Out $1.33 - $2.37
($1.72)
$ 0.54-69%Sold Out0
NAVBJohn Keeley 2015-06-30 Buy $1.24 - $1.67
($1.45)
$ 0.54-63%New holding10,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NAVB is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


NAVB: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
LARSON BRENT LEVP, CFO, Treas & Sec'y 2015-12-01Sell12,500$1.5-64view
LARSON BRENT LEVP, CFO, Treas & Sec'y 2015-11-02Sell12,500$1.98-72.73view
LARSON BRENT LEVP, CFO, Treas & Sec'y 2015-10-01Sell12,500$2.27-76.21view
LARSON BRENT LEVP, CFO, Treas and Sec'y 2015-09-01Sell12,500$1.88-71.28view
LARSON BRENT LEVP, CFO, Treas and Sec'y 2015-08-03Sell12,500$1.71-68.42view
LARSON BRENT LEVP, CFO, Treas and Sec'y 2015-06-01Sell12,500$1.24-56.45view
Troup Gordon ADirector 2015-05-29Buy10,000$1.31-58.78view
FORD BRENDAN ADirector 2015-05-21Buy20,000$1.31-58.78view
LARSON BRENT LEVP, CFO, Treas and Sec'y 2015-05-01Sell12,500$1.33-59.4view
LARSON BRENT LEVP, CFO, Treas and Sec'y 2015-04-01Sell20,000$1.58-65.82view

Quarterly/Annual Reports about NAVB:

News about NAVB:

Articles On GuruFocus.com
Navidea Biopharmaceuticals Reports 4 Insider Trades Mar 18 2013 

More From Other Websites
ETF’s with exposure to Navidea Biopharmaceuticals, Inc. : July 20, 2016 Jul 20 2016
Navidea Receives IRB Approval for its Lymphoseek® Rheumatoid Arthritis Clinical Trial Protocol Jul 19 2016
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure Jul 18 2016
Platinum Partners to Shut Down Main Fund; Here Are Its 5 Stock Picks Jul 05 2016
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 29 2016
ETF’s with exposure to Navidea Biopharmaceuticals, Inc. : June 17, 2016 Jun 17 2016
Navidea Announces Presentation of Results Demonstrating Performance of Lymphoseek® in Breast Cancer... Jun 16 2016
Navidea Announces Presentation of Results Demonstrating Performance of Lymphoseek® in Breast Cancer... Jun 16 2016
Navidea to Provide Shareholder Update Jun 14 2016
Navidea to Provide Shareholder Update Jun 14 2016
Navidea Biopharmaceuticals, Inc. :NAVB-US: Earnings Analysis: Q1, 2016 By the Numbers : June 3, 2016 Jun 03 2016
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Triggering Events That Accelerate or Increase a... Jun 02 2016
Navidea Announces Data Presentations at 2016 Annual Meeting of the Society of Nuclear Medicine and... Jun 02 2016
Navidea Announces Data Presentations at 2016 Annual Meeting of the Society of Nuclear Medicine and... Jun 02 2016
$1.8 Million Fast-Track NIH SBIR Grant for Manocept™ Immunotherapeutics Evaluation in Kaposi’s... May 26 2016
$1.8 Million Fast-Track NIH SBIR Grant for Manocept™ Immunotherapeutics Evaluation in Kaposi’s... May 26 2016
NAVIDEA BIOPHARMACEUTICALS, INC. Financials May 25 2016
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Triggering Events That Accelerate or Increase a... May 24 2016
Navidea Provides Financing Update May 23 2016
Navidea Provides Financing Update May 23 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)